The short answer
There is no established spacing interval or universal avoidance rule for DL-alpha-lipoic acid with insulin isophane. Glucose review is sensible, and the reported autoimmune low-glucose problem is a separate mechanism.
What this answer covers
Oral DL racemate versus R-alpha-lipoic acid or unspecified ALA preparations; human NPH subcutaneous insulin.
- Supplement or preparation
- DL-alpha-Lipoic acid
- Medication ingredient
- insulin isophane
Spacing has not been demonstrated
The inspected clinical sources do not test whether taking DL-alpha-lipoic acid hours apart from NPH changes risk. A metabolic effect cannot be assumed to disappear with a short gap.
The racemic trial measured sensitivity
A pilot study found greater insulin-stimulated glucose disposal with oral racemic alpha-lipoic acid. That laboratory measure does not establish NPH-specific hypoglycemia or a dose that requires universal avoidance.
Autoimmune reports are different
Alpha-lipoic-acid-associated insulin autoimmune syndrome concerns an antibody-related cause of low glucose. The cases do not demonstrate increased action of injected NPH, and the inspected abstract does not verify the DL formulation.
Use the current precaution
Health Canada’s DL/R monograph advises diabetes consultation and low-glucose precautions under its labeling conditions. Those conditions are not a safe-dose boundary. Discuss the exact product and amount with the diabetes team before starting or stopping it. Follow your glucose-monitoring and low-glucose treatment plan. Do not adjust insulin yourself.
Evidence and practical considerations
Timing & monitoring
No established spacing interval or universal avoidance rule for this exact preparation with NPH; glucose review remains appropriate.
- Exact scope
- Oral DL racemate versus R-alpha-lipoic acid or unspecified ALA preparations; human NPH subcutaneous insulin. with Insulin isophane RxCUI1605101 IN; human NPH subcutaneous suspension label bridge.
- Medication form and route
- subcutaneous insulin isophane; oral supplement
What remains uncertain
- No exact event rate or arbitrary dose adjustment.
Factors that may matter: Product; Dose; Meals; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed human NPH insulin
Hypoglycemia can be severe. Niacin may reduce glucose lowering. Changes in glucose-active treatments and meals can require monitoring and clinician review. Intravenous and pump use prohibited.
How this applies: RxCUI1605101 IN insulin isophane; human NPH formulation bridge explicit.
Human NPH labels inform the generic insulin-isophane ingredient. Not animal insulin, rapid analogs or automatically every premix. No herb-specific event rate.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed human NPH insulin
Hypoglycemia can be severe. Niacin may reduce glucose lowering. Changes in glucose-active treatments and meals can require monitoring and clinician review. Intravenous and pump use prohibited.
How this applies: RxCUI1605101 IN insulin isophane; human NPH formulation bridge explicit.
Human NPH labels inform the generic insulin-isophane ingredient. Not animal insulin, rapid analogs or automatically every premix. No herb-specific event rate.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 74people with type2diabetes.
Pooled active racemic alpha-lipoic-acid groups had increased insulin-stimulated glucose disposal versus placebo.
How this applies: Indirect for human NPH insulin; racemate, R-form and unspecified ALA products distinguished.
Exploratory pilot and pooled active doses, no insulin-isophane regimen or clinical hypoglycemia incidence; insulin sensitivity is not itself an adverse event.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Two women with insulin autoimmune syndrome.
Two women developed insulin autoimmune syndrome associated with alpha-lipoic acid; genetic susceptibility identified.
How this applies: Indirect for human NPH insulin; racemate, R-form and unspecified ALA products distinguished.
Case reports do not prove an insulin-isophane interaction; exact stereochemical preparation not established in abstract. Autoimmune endogenous-insulin mechanism distinct from additive injected-insulin action.
Source 5: current natural-health-product monograph
webprod.hc-sc.gc.ca · Source check Sep 10, 2026
Population: Adults considering covered alpha-lipoic-acid products.
Covered products require diabetes consultation advice and low-glucose symptom precautions under stated labeling conditions.
How this applies: Indirect for human NPH insulin; racemate, R-form and unspecified ALA products distinguished.
Labeling thresholds are not proven safe-dose cutoffs. Not an NPH-specific interaction study.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact isophane article with human NPH product bridge and source-specific clinical limits. | |
| Research summary published |
Article revision: 0a50116b1583ff9d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.